Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Present treatment for chronic obstructive pulmonary disease (COPD) has a certain role in
reducing COPD exacerbation and hospitalization, improving the life quality, and postponing
the lung function decline. But for some patients with severe COPD, current treatment only
partially alleviates the symptoms and has little role in the lung function decline. In this
randomized, multicenter study, the investigators evaluate the safety and efficacy of bosentan
in the treatment of grade Ⅲ or Ⅳ COPD patients with pulmonary hypertension detected by
echocardiography. The primary endpoint is the frequency of COPD exacerbation, and the
secondary endpoint includes changes of lung function, 6-min-walk distance (6-MWD), SGRQ score
and mMRC/CAT score.
Phase:
Phase 2
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University
Treatments:
Bosentan Budesonide, Formoterol Fumarate Drug Combination